Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

NCT02290210 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout
Hyperuricemia

Interventions

DRUG: URC102 0.25mg
DRUG: URC102 0.5mg
DRUG: URC102 1.0mg
DRUG: URC102 2.0mg
DRUG: placebo

Sponsor

JW Pharmaceutical